Analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the medical technology company’s stock.
BIOLASE Price Performance
Shares of NASDAQ BIOL opened at $0.01 on Thursday. The stock has a market capitalization of $237,189.70, a price-to-earnings ratio of 0.00 and a beta of 0.67. The business has a 50-day moving average of $0.01 and a 200-day moving average of $0.02. BIOLASE has a fifty-two week low of $0.02 and a fifty-two week high of $1.94.
BIOLASE Company Profile
Featured Articles
- Five stocks we like better than BIOLASE
- Where Do I Find 52-Week Highs and Lows?
- FedEx Delivers Another Crushing Blow to Its Stock Price
- How to Find Undervalued Stocks
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- The Significance of Brokerage Rankings in Stock Selection
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.